AIM ImmunoTech股票讨论区

$AIM ImmunoTech(AIM.US)$ 👀

$AIM ImmunoTech(AIM.US)$ AIM ImmunoTech宣布在Ampligen和Imfinzi作为晚期胰腺癌联合疗法的1B/2期研究中，首剂量水平总体上耐受性良好

$AIM ImmunoTech(AIM.US)$ 来个1块吧

$AIM ImmunoTech(AIM.US)$
NEWS
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased an...

$AIM ImmunoTech(AIM.US)$ AIM ImmunoTech宣布在《临床癌症研究》杂志上发表一项评估Ampligen® 治疗胰腺癌的研究的积极发现

$AIM ImmunoTech(AIM.US)$ AIM ImmunoTech 在 2 分钟前，美国东部时间上午 8:50 通过 GLOBENEWSWIRE 报告了评估Ampligen® 治疗新冠肺炎后疾病的 2 期研究的积极结果

$AIM ImmunoTech(AIM.US)$ AIM ImmunoTech 获得伊拉斯谟医学中心伦理委员会批准，进行用于治疗局部晚期胰腺癌的 Ampligen® 二期研究 3 分钟前，美国东部标准时间上午 9:10 通过 GLOBENEWSWIRE

$AIM ImmunoTech(AIM.US)$ AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

$AIM ImmunoTech(AIM.US)$ AIM Immunitech颁发了两项美国专利，标题为 “癌症治疗组合物和方法” 和 “提高肌痛性脑脊髓炎患者运动耐受性的方法”